Table 2.
Primary and secondary outcome measures of the modified intention-to-treat population
| Posaconazole prophylaxis (n = 37) |
Standard-of-care (n = 36) |
p value | |
|---|---|---|---|
| Primary endpointa | |||
| IAPA incidence during ICU stay | 2 (5.4%) | 4 (11.1%) | 0.32 |
| Between-group difference (95% CI) IAPA incidence | 5.7% (− 10.8 to 21.7) | – | – |
| Secondary endpoints | |||
| Timing IAPA diagnosisb | |||
| Median timing of IAPA diagnosis after ICU admission—days (IQR) | 10 (8–12) | 5 (3–8) | 0.27 |
| Length of stayc | |||
| Median length of ICU stay—days (IQR) | 16 (8–29), n = 30 | 6 (3–12), n = 27 | 0.76 |
| Median length of hospital stay—days (IQR) | 25 (18–45), n = 28 | 12 (9–35), n = 25 | 0.56 |
| Mortalityd | |||
| ICU | 7 (18.9%) | 9 (25.0%) | 0.58 |
| Between group difference (95% CI) ICU mortality | 6.1% (− 14.3 to 26.9) | – | – |
| Hospital | 8 (21.6%) | 10 (27.8%) | 0.60 |
| Between group difference (95% CI) hospital mortality | 6.2% (− 14.8 to 27.6) | – | – |
| 90-day | 9 (24.3%) | 11 (30.6%) | 0.61 |
| Between group difference (95% CI) 90-day mortality | 6.2% (− 15.1 to 8.2) | – | – |
CI confidence interval, IAPA influenza-associated pulmonary aspergillosis, ICU intensive care unit, IQR interquartile range
ap value based on a one-sided Fisher’s Exact test, confidence interval for comparison of proportions based on the Newcombe-Wilson method
bTime to onset of IAPA was evaluated with the use of the Kaplan–Meier analysis and two-sided log-rank test, patient data were censored at 90 days after ICU admission
cLength of stay was defined as the time to discharge alive, while death was considered as a competing event. Median and IQR of days to alive discharge are shown. Two-sided statistical significance testing was performed using Gray’s test for competing event data
dp value based on a two-sided Fisher’s Exact test, confidence interval for comparison of proportions based on the Newcombe-Wilson method